Please ensure Javascript is enabled for purposes of website accessibility

Why Teva Pharmaceutical Is Soaring 13.5% Today

By Todd Campbell – Dec 14, 2017 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A corporate restructuring is boosting hope that the company can overcome significant headwinds.

What happened

After providing investors with the details of its latest cost-savings plan, including a massive workforce reduction, Teva Pharmaceutical (TEVA 0.65%) shares are rallying 13.5% as of 1 p.m. EST Thursday.

So what

It's been a brutal year for the world's biggest generic drugmaker. Shares have suffered significantly due to declining sales and profit due to lower generic drug prices, new competition for its best-selling drug, Copaxone, and higher interest expenses associated with its $40 billion acquisition of Allergan's (AGN) generic drug business.

A computer monitor displaying stock price quotes and an upwardly trending share price bar chart.

Image source: Getty Images.

In the third quarter, these headwinds caused non-GAAP (generally accepted accounting principles) profit to tumble 23.7% year over year to $1 per share. Revenue from generic drugs dropped 7.7% to $3 billion and Copaxone sales fell 7% to $987 million, which in turn, caused specialty brand drug revenue to fall 1% to $2 billion.

Unfortunately, the top-line headwinds negatively impacting Teva Pharmaceutical's profit aren't going to ease up anytime soon, especially since Mylan (MYL) launched a Copaxone competitor in Q4 that could significantly dent Copaxone sales in 2018.

In response to its revenue challenges, management outlined a plan on Thursday to conserve cash, pay down debt, and keep itself afloat. The plan includes eliminating 25% of its workforce (14,000 jobs) and suspending its dividend payment to investors. The company won't pay any bonuses this year and it plans to ax management and close some of its buildings. Overall, it thinks these moves will save it more than $1.5 billion by the end of 2018 and $3 billion by the end of 2019. 

Management also told investors it will update them in February on its long-term strategy and that it doesn't plan on issuing more shares to raise cash. 

Now what

These are painful but necessary moves if Teva Pharmaceutical's is going to survive. The dividend cut is disappointing, but not unexpected given that it previously cut its dividend by 75% earlier this year to free up cash.

The troubles facing the company remain big, though, and I'm uncertain these moves make this company a buy. Debt remains above $35 billion and while cash flow is still positive, the size of the negative impact that's associated with Mylan launching its 40 mg formulation of Copaxone won't be clear for a while. Given the risks and lack of a dividend anymore, there are probably better places to invest your money.

Todd Campbell owns shares of Mylan. His clients may have positions in the companies mentioned. 
The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.74 (0.65%) $0.05
Allergan plc Stock Quote
Allergan plc
Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.